TP53 and ovarian carcinoma: Although not unanimously, it has been shown in experimental and pilot clinical studies that ovarian carcinomas with TP53 gene mutations show a better response to paclitaxel or paclitaxel containing regimens than tumors with normal TP53 [6,12,13,21-26]; however, these results have been obtained in univariate analyses only.